Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Danielle Johnston-Blackwell"'
Autor:
Michael J. Thomenius, Alejandra Raimondi, Scott A. Ribich, Sarah K. Knutson, Elayne Chan-Penebre, Heike Keilhack, Robert A. Copeland, Jesse J. Smith, Christopher Plescia, Igor Feldman, Natalie M. Warholic, Vinny Motwani, Trupti Lingaraj, Allison Drew, Danielle Johnston-Blackwell, Dorothy Brach
The EZH2 small-molecule inhibitor tazemetostat (EPZ-6438) is currently being evaluated in phase II clinical trials for the treatment of non-Hodgkin lymphoma (NHL). We have previously shown that EZH2 inhibitors display an antiproliferative effect in m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16635ec96cb32a617f49970fa6370768
https://doi.org/10.1158/1535-7163.c.6539623.v1
https://doi.org/10.1158/1535-7163.c.6539623.v1
Autor:
Michael J. Thomenius, Alejandra Raimondi, Scott A. Ribich, Sarah K. Knutson, Elayne Chan-Penebre, Heike Keilhack, Robert A. Copeland, Jesse J. Smith, Christopher Plescia, Igor Feldman, Natalie M. Warholic, Vinny Motwani, Trupti Lingaraj, Allison Drew, Danielle Johnston-Blackwell, Dorothy Brach
Table S1: Conditions and seeding densities of all cell lines used in studies; Table S2. Single agent IC50 values for agents tested for 3 days in 96-well plates as described in Materials and Methods; Figure S1. Tazemetostat dosing reduced H3K27me3 in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::028053566081cf3c139a50ed258075a7
https://doi.org/10.1158/1535-7163.22510432
https://doi.org/10.1158/1535-7163.22510432
Autor:
Sarah K. Knutson, Scott Ribich, Allison Drew, Heike Keilhack, Igor Feldman, J. Joshua Smith, Danielle Johnston-Blackwell, Michael Thomenius, Christopher Plescia, Elayne Chan-Penebre, Trupti Lingaraj, Robert A. Copeland, Vinny Motwani, Alejandra Raimondi, Natalie Warholic, Dorothy Brach
Publikováno v:
Molecular Cancer Therapeutics. 16:2586-2597
The EZH2 small-molecule inhibitor tazemetostat (EPZ-6438) is currently being evaluated in phase II clinical trials for the treatment of non-Hodgkin lymphoma (NHL). We have previously shown that EZH2 inhibitors display an antiproliferative effect in m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cba4e6445ef53b25230ed1edf2577da9
https://doi.org/10.1158/1535-7163.mct-16-0840
https://doi.org/10.1158/1535-7163.mct-16-0840
